What happened
Colgate Palmolive Co (NYSE: CL) CEO Noel R. Wallace sold 20,000 shares on Nov. 5 for about $2.01 million.
Wallace, who is also the company's chairman, president and a director, reported the sale on a Form 4 signed Nov. 6. The form lists the transaction under code S, the form's sale code. The shares sold at a weighted average of $100.26, in multiple transactions priced from $100.01 to $100.51.
After the sale, Wallace held 359,700 shares directly. The filing also lists three indirect holdings. These are shares owned through a plan or trust rather than in Wallace's own name. They are 55,173 through the issuer's 401(k) plan trustee, 52,000 through a spouse trust and 335 through another trust.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 20,000 | SEC Form 4 | |
| Weighted average price | $100.26 | SEC Form 4 | |
| Total sale value | about $2.01 million | SEC Form 4 | |
| Shares held directly after sale | 359,700 | SEC Form 4 | |
| Share of direct holding sold | 5.3% | Calculated from SEC Form 4 |
Read more: Colgate Palmolive (CL) company research
Why it matters
The sale trims Wallace's direct stake without ending it. OptimistFi calculates that the shares sold were 5.3% of the 379,700 held directly before the trade.
OptimistFi has argued that Colgate converts brand scale, pricing and productivity into predictable cash flow that funds dividends, buybacks and steady EPS growth. One executive's sale of this size leaves that view unchanged.
Wallace still owns shares directly, through the 401(k) plan and through two trusts, so the position is smaller but intact. The sale reduced only the directly held shares. The 401(k) plan and trust holdings listed in the filing stay as reported after the trade. A sale by one executive is not a read on how Colgate's business is performing.
The price range was narrow. The shares sold within 50 cents, from low to high, so the weighted average is a fair guide to each piece of the sale.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Colgate's next quarterly report is the next scheduled test of the case OptimistFi describes. Continued cash flow and EPS growth would keep this sale in context, while a slowdown in either would make it harder to set aside.
The report will show whether pricing and productivity are still turning into the cash flow that funds dividends and buybacks.
More from OptimistFi
- CL stock: research and coverage of Colgate Palmolive
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
Sources
- SEC Form 4, Noel R. Wallace, Colgate Palmolive Co — Statement of changes in beneficial ownership covering the Nov. 5, 2026 sale, signed Nov. 6, 2026
Explore OptimistFi research on Colgate Palmolive Co: https://optimistfi.com/stocks/CL
Browse Colgate Palmolive Co company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the Colgate Palmolive Co company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
